{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:29:47Z","timestamp":1788535787735,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006513","name":"Duke Clinical Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006513","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["heartrhythmopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Rhythm O2"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.hroo.2022.09.018","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T02:05:01Z","timestamp":1664330701000},"page":"621-628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"PA","title":["Residual stroke risk despite oral anticoagulation in patients with atrial fibrillation"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8134-366X","authenticated-orcid":false,"given":"Matthew A.","family":"Carlisle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Shrader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marat","family":"Fudim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen S.","family":"Pieper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalia G.","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald V.","family":"Naccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard J.","family":"Gersh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Reiffel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Kowey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James V.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Ezekowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry A.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean D.","family":"Pokorney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0772-2404","authenticated-orcid":false,"given":"Jonathan P.","family":"Piccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hroo.2022.09.018_bib1","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart disease and stroke statistics\u20142019 update: a report from the American Heart Association","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.hroo.2022.09.018_bib2","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1161\/CIRCULATIONAHA.117.028981","article-title":"Sex differences and similarities in atrial fibrillation epidemiology, risk factors, and mortality in community cohorts: results from the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe)","volume":"136","author":"Magnussen","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.hroo.2022.09.018_bib3","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2022.09.018_bib4","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2022.09.018_bib5","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2022.09.018_bib6","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2022.09.018_bib7","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1001\/jamacardio.2016.0393","article-title":"Residual risk of stroke and death in anticoagulant-treated patients with atrial fibrillation","volume":"1","author":"Freedman","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.hroo.2022.09.018_bib8","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ahj.2011.07.001","article-title":"Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF","volume":"162","author":"Piccini","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.hroo.2022.09.018_bib9","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ahj.2014.04.005","article-title":"Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry","volume":"168","author":"Steinberg","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.hroo.2022.09.018_bib10","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2022.09.018_bib11","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2022.09.018_bib12","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2022.09.018_bib13","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2022.09.018_bib14","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1161\/CIRCULATIONAHA.112.107128","volume":"127","author":"Piccini","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.hroo.2022.09.018_bib15","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.amjcard.2012.01.371","article-title":"CHADS2 and CHA2DS2-VASc risk factors to predict first cardiovascular hospitalization among atrial fibrillation\/atrial flutter patients","volume":"109","author":"Naccarelli","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hroo.2022.09.018_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3389\/fmed.2017.00019","article-title":"Factors XI and XII as targets for new anticoagulants","volume":"4","author":"Weitz","year":"2017","journal-title":"Front Med"},{"key":"10.1016\/j.hroo.2022.09.018_bib17","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1056\/NEJMoa2101897","article-title":"Left atrial appendage occlusion during cardiac surgery to prevent stroke","volume":"384","author":"Whitlock","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2022.09.018_bib18","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1093\/eurheartj\/eht135","article-title":"Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial","volume":"34","author":"Al-Khatib","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hroo.2022.09.018_bib19","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.116.004267","article-title":"Stroke and mortality risk in patients with various patterns of atrial fibrillation: results from the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)","volume":"10","author":"Link","year":"2017","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.hroo.2022.09.018_bib20","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/eurheartj\/ehu359","article-title":"Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial","volume":"36","author":"Steinberg","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hroo.2022.09.018_bib21","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1136\/bmj.305.6867.1460","article-title":"Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and long term prognosis (Oxfordshire community stroke project)","volume":"305","author":"Sandercock","year":"1992","journal-title":"BMJ"},{"key":"10.1016\/j.hroo.2022.09.018_bib22","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1161\/CIRCULATIONAHA.118.035909","article-title":"Adherence to guideline-directed stroke prevention therapy for atrial fibrillation is achievable","volume":"139","author":"Piccini","year":"2019","journal-title":"Circulation"}],"container-title":["Heart Rhythm O2"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666501822002367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666501822002367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:25:32Z","timestamp":1762993532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666501822002367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2666501822002367"],"URL":"https:\/\/doi.org\/10.1016\/j.hroo.2022.09.018","relation":{},"ISSN":["2666-5018"],"issn-type":[{"value":"2666-5018","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Residual stroke risk despite oral anticoagulation in patients with atrial fibrillation","name":"articletitle","label":"Article Title"},{"value":"Heart Rhythm O2","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hroo.2022.09.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Heart Rhythm Society. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}